Nintedanib for treating progressive fibrosing interstitial lung diseases

被引：4
|
作者：
Adler, Amanda, I [1 ]
Guo, Yelan [2 ]
Thiam, Aminata [2 ]
Elliott, Nicole [2 ]
Patel, Sanjeev [3 ]
机构：
[1] Biomed Res Ctr, Oxford Ctr Diabet Endocrinol & Metab, Diabet Trial Unit, Oxford, England
[2] Natl Inst Hlth & Care Excellence, Manchester, Lancs, England
[3] Kings Coll Hosp London, Dept Rheumatol, London, England
来源：
LANCET RESPIRATORY MEDICINE | 2021年 / 9卷 / 12期
关键词：
D O I：
10.1016/S2213-2600(21)00517-8
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：E116 / E117
页数：2
相关论文
共 50 条
  • [21] Does HRCT pattern influence the effect of nintedanib in patients with progressive fibrosing interstitial lung diseases?
    Behr, J.
    Brown, K. K.
    Walsh, S. L. F.
    Devaraj, A.
    Song, J. W.
    Wuyts, W. A.
    Valenzuela, C.
    Goeldner, R. G.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    PNEUMOLOGIE, 2021, 75 : S31 - S32
  • [22] Does HRCT Pattern Influence the Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases?
    Brown, K. K.
    Walsh, S. L. F.
    Devaraj, A.
    Song, J.
    Wuyts, W. A.
    Valenzuela, C.
    Goeldner, R.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [23] Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial
    Inoue, Yoshikazu
    Wells, Athol U.
    Song, Jin Woo
    Xu, Zuojun
    Kitamura, Hideya
    Suda, Takafumi
    Okamoto, Masaki
    Mueller, Heiko
    Coeck, Carl
    Rohr, Klaus B.
    Kolb, Martin
    Brown, Kevin K.
    RESPIROLOGY, 2023, 28 (05) : 465 - 474
  • [24] Effects of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) by Composite Physiologic Index (CPI)
    Nambiar, A. M.
    Molina-Molina, M.
    Padilla, M.
    Song, J.
    Mueller, H.
    Stowasser, S.
    Rohr, K. B.
    Wells, A. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [25] Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analyses from the INBUILD Trial
    Kolb, M. R.
    Flaherty, K. R.
    Silva, R. S.
    Prasse, A.
    Patel, N. M.
    Vancheri, C.
    Quaresma, M.
    Goeldner, R.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [26] BEYOND CLINICALTRIALS: EFFICACY AND SAFETY OF NINTEDANIB IN IPF AND PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES IN CLINICAL PRACTICE
    De Gracia, A. I.
    Bea, C.
    Fuertes, E.
    De Castro, A.
    Navarro, L.
    Prades, C.
    Ruiz, D.
    Albiol, P.
    Forner, M. J.
    Vela-Bernal, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1662 - 1663
  • [27] Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
    Cottin, Vincent
    EUROPEAN RESPIRATORY REVIEW, 2019, 28 (153):
  • [28] Nintedanib in chronic fibrosing interstitial lung diseases. A case series
    Sevila, Raquel Garcia
    Jimenez, Juan Jose Arenas
    Casasempere, Paloma Vela
    Perez, Ester Nofuentes
    Garcia-Manso, Ignacio Gaya
    HELIYON, 2024, 10 (07)
  • [29] The natural history of progressive fibrosing interstitial lung diseases
    Kolb, Martin
    Vasakova, Martina
    RESPIRATORY RESEARCH, 2019, 20 (1)
  • [30] Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
    Albera, Carlo
    Verri, Giulia
    Sciarrone, Federico
    Sitia, Elena
    Mangiapia, Mauro
    Solidoro, Paolo
    BIOMEDICINES, 2021, 9 (09)
12345